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Abstract
Background: The metabolic syndrome (MetS) is a cluster of risk factors associated with morbidity from
cardiovascular disease (CVD) and associated mortality. Russia has one of the highest CVD mortality rates in the
world. However, the prevalence of MetS in Russia remains largely unknown. The aim of this study is to estimate
the prevalence of MetS and its components in an urban Russian setting.
Methods: Altogether, 3705 Russian adults aged 18-90 years were enrolled in a cross-sectional study in Arkhangelsk
(Northwest Russia). All subjects completed a questionnaire and underwent a physical examination. Blood samples
were taken and analyzed in TromsØ, Norway. Three separate modified definitions of MetS were used, namely, the
National Education Cholesterol Education Program Adult Treatment Panel III (NCEP), the American Heart
Association/National Heart, Lung and Blood Institute (AHA/NHLBI) and the International Diabetes Federation (IDF).
To ensure comparability of the findings, the prevalence data were standardized using world and European
standard populations and Russian population.
Results: The age-standardized (Segi’s world standard population) prevalence rates of the MetS among women
were 19.8% (95% CI: 18.1-21.5), 20.6% (95% CI: 18.9-22.3) and 23.1% (95% CI: 21.3-24.9) by the NCEP, AHA/NHLBI
and IDF criteria, respectively. The corresponding rates for men were 11.5% (95% CI: 10.1-12.9), 13.7% (95% CI: 12.2-
15.2) and 11.0% (95% CI: 9.7-12.4). Among subjects with MetS, central obesity was more common among women,
while elevated triglycerides and blood glucose were more common among men. Almost perfect agreement was
found between the NCEP and AHA/NHLBI criteria ( = 0.94). There was less agreement between the used
definitions of MetS in men than in women.
Conclusions: While the prevalence of MetS among Russian women is comparable to the data for Europe and the
U.S., the prevalence among Russian men is considerably lower than among their European and North-American
counterparts. Our results suggest that MetS is unlikely to be a major contributor to the high cardiovascular
mortality among Russian men. Further studies of MetS determinants and associated cardiovascular risk are needed
for a better understanding of the mechanisms leading to the exceptionally high cardiovascular mortality in Russia.
Background
MetS is an unfavourable cluster of factors that increases
the risk of CVD and type-2 diabetes [1-3]. MetS is asso-
ciated with more than 50% increased risk of cardiovas-
cular mortality and an almost 30% enhanced risk of
mortality from all causes [4-6]. It is a considerable
public health issue in both developed and developing
countries. In general, its prevalence in Europe and
among Americans of European descent varies between
20% and 30%, with approximately equal distribution by
gender [7-11]. Although genetic predisposition has been
suggested as an important determinant of MetS [12],
genetic factors alone cannot explain the recent increase
in prevalence in both Europe and the U.S.
* Correspondence: Oleg.Sidorenkov@ism.uit.no
1Institute of Community Medicine, University of Tromsø, postbox 9037
Tromsø, Norway
Sidorenkov et al. BMC Public Health 2010, 10:23
http://www.biomedcentral.com/1471-2458/10/23
© 2010 Sidorenkov et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.Internationally, there is no uniform accepted definition
of MetS. Altogether, six sets of diagnostic criteria have
been proposed by different expert groups. Despite con-
siderable similarity among the definitions, the prevalence
of the MetS in the same population may vary dramati-
cally depending on the specificd i a g n o s t i cc r i t e r i ac o n -
sidered [13]. This complicates international comparisons
and may challenge estimates of the global burden of the
syndrome.
While cardiovascular mortality in Western Europe and
the U.S. has decreased during recent decades, the oppo-
site trend has been observed in Russia where it has
increased from 412 per 100,000 in 1970 to 927 per
100,000 in 2003. Mortality from cardiovascular diseases
in Russia is currently the highest in Europe. In 2003,
CVDs accounted for about 56% of all deaths [14]. Cor-
onary heart disease and cerebrovascular diseases alone,
respectively, constituted 26 % and 20% of the total mor-
tality. The highest increase in CVD has occurred among
30-60 year-olds, particularly among men [15].
Given that MetS is a strong predictor of cardiovascu-
lar mortality and morbidity [4-6], one may suspect a
high prevalence of this syndrome in contemporary Rus-
sia. Few studies have described the prevalence of dyslipi-
demia, hypertension and obesity among Russians
[16,17]. The actual rates reported were either compar-
able to or lower than those in Europe [18]. These stu-
dies, however, focused only on the distribution of major
cardiovascular risk factors. To the best of our knowl-
edge, no large Russian population-based studies on clus-
ter of the major cardiovascular risk factors, such as the
MetS, have been published.
The aim of the present study is to estimate the preva-
lence of MetS and its components in an urban Russian
setting using several international definitions and refer-
ence populations to ensure comparability of the
findings.
Methods
Sample characteristics
The survey was conducted in 2000 in Arkhangelsk, the
capital of the Arkhangelsk Region of Russia. The popu-
lation of Arkhangelsk prior to the study’s initiation was
approximately 170,000 men and 197,000 women. The
city is ethnically homogenous: 95% of inhabitants are
registered as Russians and most of the reminder are eth-
nically and culturally close to Russians (e.g. 2% of the
population are registered as Ukrainians and 1% as
Byelorussians).
No population register for medical research exists in
Arkhangelsk. Primary health care departments provide
medical services to the general population within the
regional general health and occupational health network.
People are registered at polyclinics according to their
home address and/or place of work. All study partici-
pants when registered at the same out-patient clinic in
Arkhangelsk. Of those who were invited, only 40 per-
sons (1.1 %) refused to participate with “lack of time” as
the primary reason given. Individuals coming for their
annual medical check-up at the out-patient clinic were
recruited consecutively to avoid the “healthy volunteer
effect”. Workers and students were similarly invited
either through the obligatory annual medical examina-
tion or through their places of work or study. Pen-
sioners were recruited through the clinic’sr e g i s t e r .
About 90% of males and 70% of females were recruited
through an annual medical examination consisting
mainly of working people but also students, pensioners
and unemployed individuals. Other subjects were invited
to the study. Students constituted approximately 12%,
pensioners 19%, unemployed 3% and working subjects
66 % of the study population.
Altogether, 1968 men and 1737 women aged 18-90
years participated in the study. It involved a physical
examination, completion of a comprehensive question-
naire and donating blood for tests. Data were collected
by trained medical personnel. The study was approved
by the Regional Ethics Committee, TromsØ, Norway.
Verbal informed consent was obtained from all
participants.
Data collection
Anthropometric measurements included weight, height,
waist and hip circumference. Body mass index (BMI)
and waist-to-hip ratio (WHR) were calculated. Blood
pressure and heart rate were measured (upper right
arm) in a sitting position three times at two minute
intervals using a semiautomatic electronic device
(DINAMAP-R, Criticon, Tampa, Florida). Averages of
the second and third systolic and diastolic blood pres-
sure readings were used in the analysis. In addition, all
subjects completed a six-page questionnaire on socio-
demographic characteristics, medicines used (including
regular intake of antihypertensive and anti-diabetic med-
ications), smoking habit, alcohol consumption, diet and
level of physical activity during leisure time and at work.
History of cardiovascular diseases and diabetes were
assessed by additional questions preceded by “do you
now have or have you ever had” angina pectoris (AP),
myocardial infarction (MI), stroke or diabetes mellitus
( D M ) .O n l yb a s i cs o c i o - d e m o g r a p h i cd a t aa n ds e l f -
reported diseases are presented for descriptive purposes
in this paper. Age was categorized into five groups: 18-
29, 30-39, 40-49, 50-59 and 60+ years. Education was
classified as secondary or lower, vocational, incomplete
higher, or higher. Income level was very difficult to
determine during the year 2000 owing to high inflation
and a collapsing economy, with about 30% of the
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vival minimum[19]. Consequently, we used self-reported
occupational status data as a surrogate measure of
income. Assigned income levels were based on the offi-
cial year-2000 average salary levels recorded for different
sectors of the economy [20], and were categorized as
very low, low, medium or high. The income of groups
for whom there were no official salary data (for example,
students, the unemployed and housewives) was classified
as unknown. Cigarette smoking was categorized as “yes”
(occasional or daily smokers) or “no” (non-smokers or
ex-smokers). Data on frequency of alcohol consumption
were obtained by asking “How often do you drink alco-
holic beverages?”. More details about the study, recruit-
ment details, sample and data collection protocols are
presented elsewhere [21,22].
Laboratory measurements
Venous blood samples were drawn in the morning and
centrifuged within 15-25 minutes in the laboratory at
the study site in Arkhangelsk. Because subjects generally
fast in preparation for these annual medical check-ups,
since screening for diabetes and impaired glucose toler-
ance is part of the examination, we assume that most of
the study participants indeed fasted. Nevertheless, none
of them was directly asked by the study team to fast
prior to the medical examination. The serum samples
were stored at -20°C and then transported frozen to
Norway where they were kept at -80°C pending analysis.
Total serum cholesterol (TC), triglycerides (TG), high-
density lipoprotein cholesterol (HDL-C), serum glucose
(SG) and glycosylated hemoglobin (HBA1c) were mea-
sured. All laboratory analyses were carried out at the
Department of Clinical Chemistry, University Hospital
of Northern Norway (UNN) in Tromsø.
Enzymatic colorimetric tests were used to measure TC
(cholesterol esterase, cholesterol oxidase) and TG (lipo-
protein lipase, glycerokinase, and glycerophosphate oxi-
dase). HDL-C was measured by a homogenous enzymatic
colorimetric test (PEG cholesterol esterase, and PEG per-
oxidase). The coefficients of variation (CV) were, respec-
tively, 5%, 2% and 3% for the TC, TG and HDL-C
determinations. All biochemical analyses of serum lipids
were performed using a Hitachi 737 analyzer. SG was
measured by the hexokinase method using a Hitachi 917
analyzer (CV = 2%). HBA1c concentration was determined
using the Bio-Rad Variant II HPLC system with reagents
from Bio-Rad Laboratories (Inc., Hercules, CA 94547,
USA), with CV <5%. The laboratory routinely participates
in formal quality assurance exercises.
Definition of the metabolic syndrome
MetS was defined according to the National Cholesterol
Education Program Adult Treatment Panel III (NCEP)
[23], the American Heart Association/National Heart,
Lung and Blood Institute (AHA/NHLBI) version [24]
and the International Diabetes Federation (IDF) [25].
Statistical analysis
The prevalence estimates were standardized by age
using Segi’s world standard population, European stan-
dard population and Russian population (based on data
from the National Census in 2002) [26]. The following
age-strata were used: 20-29, 30-39, 40-49, 50-59 and 60
+ years. Ninety-five percent confidence intervals (CI)
were calculated for all prevalence estimates. Gender dif-
ferences in socio-demographic and some life-style char-
acteristics were compared using Pearson’s chi-squared
tests and unpaired t-tests for categorical and numerical
data, respectively. To identify sex-specific cut-offs for
waist circumference values corresponding to BMIs of
≥25 kg/m
2 and ≥30 kg/m
2, a receiver operating charac-
teristic (ROC) analysis was carried out. Agreement
between different diagnostic criteria for MetS was
assessed by Cohen’s kappa statistic. All analyses were
performed using SPSS version 14 (SPSS Inc, Chicago,
IL).
Results
Description of the study sample
Among the 3705 study participants, 150 (4.0%) had
missing data on one or more variables and were there-
fore excluded. The final study group included 1918 men
and 1637 women, corresponding to 95% of all those
invited.
The women were slightly older and were better edu-
cated, but had much lower income and a higher preva-
lence of self-reported diseases than men. The men
smoked more and took alcohol more frequently
(Table 1).
The prevalence of abnormally high components of
MetS as well as BMI and WHR increased with age in
both genders (Table 2), as did the overall prevalence of
MetS (Figure 1). This increase was more pronounced
among women. The prevalence of MetS was similar in
m e na n dw o m e ni nt h ey o u n g e s ta g eg r o u p( 2 . 5 %v s .
2.9%), but was almost twice as high in women as com-
pared to men in the oldest age group (44.8% vs. 24.4%).
T h ep r e v a l e n c eo fo b e s i t y( T a b l e2 )v a r i e ds t r i k i n g l y
depending on the definition employed (WC, BMI or
WHR). We performed a ROC analysis to evaluate the
applicability of the given WC cut-offs in our study sam-
ple. The WC cut-off ≥94 cm identified men with BMI
≥25 kg/m
2 with sensitivity (Se) of 0.35 and specificity
(Sp) of 0.99. The WC cut-off ≥102 cm identified men
having BMI ≥30 kg/m
2 with a Se of 0.41 and Sp of 0.99.
In men of our study setting, the BMI cut-offs of ≥25 kg/
m
2 and ≥30 kg/m
2 corresponded best to WC of ≥84 cm
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respectively. The standard WC cut-offs of ≥80 cm and
≥88 cm applied in women, which corresponded respec-
tively to BMIs of ≥25 kg/m
2 and ≥30 kg/m
2,w e r eo r i -
ginally characterized by good test properties
(respectively, Se of 0.79 and 0.87, and Sp of 0.91 and
0.88).
Prevalence of the metabolic syndrome
The overall prevalence of the MetS varied with the defi-
nition and reference population used (Table 3). Standar-
dization by Segi’s world population gave consistently
lower prevalence estimates than standardization by the
Russian population. The estimates standardized by the
European standard population were almost identical to
the latter and are therefore not presented. There was
almost perfect agreement between the estimates of MetS
in both men and women using the NCEP and AHA/
N H L B Id i a g n o s t i cc r i t e r i a( T a b l e4 ) .T h e r ew a sl e s s
agreement when the NCEP and IDF criteria were com-
pared, especially among men. A comparable disparity
was observed between the AHA/NHLBI and IDF
estimates.
Prevalence of individual metabolic abnormalities
Using the NCEP definition of MetS, hypertension was
the most frequent element in both sexes, followed by
dyslipidemia (Table 5). The prevalence of central obesity
was more than two times higher in women than in men
(82.4 vs. 37.1%). Hyperglycemia was the least frequent
MetS component in both men and women, regardless
its definition.
Almost three quarters of the men and more than two
thirds of the women in the total study sample had at
least one MetS component (Table 6). Altogether, 17.3%
had three or more metabolic abnormalities, of these,
60.7% had three, 33.0% had four, and 6.3% had all five.
Discussion
To our knowledge, this is the first relatively large study
addressing the prevalence of MetS and its components
in Russia. While the prevalence of MetS among Russian
women is comparable to the European and the USA
data, the prevalence among Russian men is considerably
lower than among their European and North-American
counterparts. The low prevalence rates of MetS com-
bined with the high cardiovascular mortality among
Russian men need to be explored in further studies.
Assessment of the MetS’ burden is the first step
towards monitoring the occurrence of the syndrome
and developing effective preventive measures for this
condition in Russia. The use of different internationally
accepted diagnostic criteria and different standardization
procedures provide a unique opportunity for compari-
son with both international and Russian studies. How-
ever, the results should be interpreted with caution,
taking into account several limitations of the study.
The method used to recruit the study population
might to a certain degree have resulted in a residual
“healthy worker effect”. Unemployed and marginalized
subsets of the population such as alcohol or drug abu-
sers and the homeless were underrepresented. Exclusion
of 150 individuals from the sample because of missing
values might represent another weakness. However, the
prevalence of individual metabolic components in this
Table 1 Baseline characteristics of the sample
Sample characteristic Men Women P
1
N%N %
Age, years 0.002
18-29 515 26.8 347 21.2
30-39 352 18.4 303 18.5
40-49 441 23.0 400 24.4
50-59 298 15.5 290 17.7
60+ 312 16.3 297 18.1
Marital status <0.001
Single 409 21.3 278 17.0
Married 1276 66.5 878 53.6
Divorced 82 4.3 182 11.1
Widow(er) 60 3.1 219 13.4
Cohabiting 91 4.7 80 4.9
Education <0.001
Secondary 435 22.7 426 26.0
Vocational 1083 56.5 669 40.9
Incomplete higher 87 4.5 105 6.4
Higher 303 16.3 437 26.7
Income <0.001
Very low 283 14.8 379 23.2
Low 136 7.1 740 45.2
Medium 144 7.5 189 11.5
High 1058 55.2 34 2.1
Unknown 297 15.5 295 18.0
Frequency of alcohol intake, % <0.001
Never 230 12.0 445 27.2
Once a month or less 434 22.6 542 33.1
2-4 times a month 979 51.0 571 34.9
2 times a week or more 275 14.3 79 4.8
Current smoking, % 1085 56.6 348 21.3 <0.001
Self-reported diseases
Diabetes mellitus 28 1.5 48 2.9 0.002
Coronary heart disease 176 9.2 195 11.9 0.008
Stroke 9 0.5 30 1.8 <0.001
Total 1918 100.0 1637 100.0
1 Calculated by Pearson’s chi-squared test
2 One Alcohol Unit (AU) is equivalent to 13.8 grams of pure ethanol
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included into analyses.
There was a potential for clinical-chemical measure-
ment errors in the study. Glucose was measured in
serum, not in plasma. Because serum has a higher con-
tent of water, the cut-off point for defining hyperglyce-
m i as h o u l db es l i g h t l yh i g h e r .M o r e o v e r ,w ea s s u m e d
that all blood samples were fasting but this was not
ensured. Thus, the estimate of the prevalence of MetS
may be inaccurate. To address these methodological
problems, we also calculated the prevalence of MetS
using two alternative criteria for hyperglycemia. The
first criterion involved accepting one of the following:
HBA1c ≥ 6.1 %, or self-reported DM, or receiving treat-
ment for high blood sugar. The HBA1c marker reflects
the average level of glycemia over the preceding 2’3
months and does not depend on fasting. In this study,
HBA1c was measured using a precise and reliable
method certified by the US National Glycohemoglobin
Standardization Program [27]. An earlier published
meta-analysis [28] and a recent systematic literature
review showed that the performance of HBA1c in
detecting type 2 diabetes was comparable with that of
fasting plasma glucose, and a cut-off point of ≥6.1 %.
was recommended [29]. The MetS rates based on the
HBA1c were the most conservative, since for the chosen
cut-off point of ≥6.1 % the test identifies subjects with
Impaired Fasting Glucose (IFG) with lower sensitivity
than those with the diabetes. Thus, some participants
having IFG were falsely labelled as having normoglyce-
mia. The second criterion involved raising the cut-offs
Table 2 Proportion of abnormal values (%)
1 for the components of the metabolic syndrome as well as body mass
index (BMI) and waist to hip ratio (WHR) by age group and gender.
Age-groups
18-29 years 30-39 years 40-49 years 50-59 years 60 and over Total
%9 5 % C I%9 5 % C I%9 5 % C I%9 5 % C I%9 5 % C I%9 5 % C I
Women
TG 6.1 3.9-9.2 9.9 6.9-14.0 21.3 17.4-25.7 29.7 24.5-35.3 37.4 31.9-43.2 20.3 18.4-22.4
HDL-C 36.3 31.3-41.6 36.3 30.9-42.0 38.0 33.3-43.0 49.3 43.4-55.2 54.5 48.7-60.3 42.3 39.9-44.8
DBP 0.3 0.02-1.9 5.6 3.4-9.0 17.3 13.8-21.4 32.8 27.5-38.5 43.4 37.8-49.3 19.0 17.1-21.0
SBP 7.5 5.0-10.9 13.9 10.3-18.4 35.8 31.1-40.7 62.1 56.2-67.6 75.8 70.4-80.4 37.6 35.3-40.0
Glucose 0.6 0.1-2.3 2.6 1.2-5.3 4.3 2.6-6.9 10.7 7.5-15.0 16.5 12.6-21.3 6.5 5.4-7.9
HBA1c 0.3 0.02-1.9 0.3 0.02-2.1 1.8 0.8-3.7 8.3 5.5-12.2 12.5 9.0-16.9 4.3 3.4-5.4
WC 4.3 2.5-7.2 14.5 10.9-19.1 32.5 28.0-37.4 47.6 41.7-53.5 49.8 44.0-55.7 29.0 26.8-31.3
BMI 3.5 1.9-6.1 13.2 9.7-17.7 21.5 17.6-25.9 35.9 30.4-41.7 33.3 28.1-39.1 20.8 18.9-22.9
WHR 3.2 1.7-5.8 7.3 4.7-10.9 18.8 15.1-23.0 31.0 25.8-36.8 33.3 28.1-39.1 18.1 16.3-20.1
Men
TG 12.0 9.5-15.1 21.3 17.2-26.0 25.4 21.5-29.8 32.2 27.0-37.9 28.2 23.4-33.6 22.6 20.7-24.5
HDL-C 27.2 23.4-31.3 17.1 13.4-21.5 24.5 20.6-28.8 32.9 27.6-38.6 38.1 32.8-43.8 27.4 25.4-29.4
DBP 1.4 0.6-2.9 17.6 13.9-22.1 33.6 29.2-38.2 39.3 33.7-45.1 42.9 37.4-48.7 24.4 22.5-26.4
SBP 22.3 18.9-26.2 39.2 34.1-44.5 52.8 48.1-57.6 68.5 62.8-73.6 78.5 73.5-82.9 48.8 46.5-51.0
Glucose 0.8 0.3-2.1 1.7 0.7-3.9 6.1 4.2-8.9 12.1 8.7-16.5 20.8 16.6-25.9 7.2 6.1-8.5
HBA1c 0.2 0.01-1.2 0 0-1.4 1.1 0.4-2.8 4.4 2.4-7.5 12.5 9.1-16.8 3.0 2.3-3.9
WC 0.8 0.3-2.1 4.3 2.5-7.1 7.5 5.3-10.5 12.1 8.7-16.5 10.6 7.5-14.7 6.3 5.3-7.5
BMI 3.3 2.0-5.3 9.1 6.4-12.7 14.7 11.6-18.5 20.1 15.8-25.2 15.4 11.7-20.0 11.6 10.2-13.1
WHR 4.9 3.2-7.2 25.0 20.6-29.9 30.2 26.0-34.7 37.9 32.4-43.7 46.8 41.2-52.5 26.3 24.4-28.4
1 Proportions of abnormal values (%) with 95 % CI. BMI, body mass index in kg/m
2 >30; TG, triglycerides ≥1,7 mmol/l; HDL-C, high-density lipoprotein cholesterol
<1,29 mmol/l (women) and <1,04 mmol/l (men); WC, waist circumference ≥88 cm (women) and ≥102 cm (men); DBP, diastolic blood pressure ≥ 85 mmHg; SBP,
systolic blood pressure ≥ 130 mmHg; Glucose, serum glucose ≥ 6,1 mmol/l or self-reported DM, or Rt for hyperglycemia; HBA1c, glycosylated haemoglobin ≥
6,1% or self-reported DM, or Rt for hyperglycemia; WHR, waist-to-hip ratio > 0,85 (women) and >0,9 (men).
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Figure 1 Sex-specific prevalence of the metabolic syndrome
across age-groups according to NCEP definition.
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AHA/NHLBI), and from 6.1 to 6.3 mmol/l (NCEP),
according to the local standards at the UNN laboratory.
Agreement between these two ad hoc definitions of
hyperglycemia was relatively fair (kappa = 0.68). How-
ever when comparing the MetS rates defined by the
NCEP criteria based on these two ad hoc definitions of
hyperglycemia, corresponding agreement was very good
(kappa = 0.97). Similar results were seen for other defi-
nitions (IDF, AHA/NHLBI). This might be rationalized
by the cluster nature of MetS and by the fact that
hyperglycemia was the least prevalent metabolic
abnormality in both genders. The impact of the latter
on the probability of having MetS was minimal.
The new estimates obtained by applying these modi-
fied criteria were slightly lower than previously
described (data not shown), but the agreements between
all three estimates were ≥0.95, suggesting that the
degree to which the prevalence of MetS was overesti-
mated in this study is small.
Our findings on the prevalence of MetS among Rus-
sian women are comparable to corresponding studies
from Europe [9-11] and the USA [7,8]. However while
in these studies the prevalence among men was equal to
or even higher than that among women, our study
shows that among men it is almost half that among
women. This remarkable disparity might be explained
by lifestyle and socio-economic differences between the
genders. Females were slightly older, better educated
and primarily employed in jobs where the level of physi-
cal activity at work was low, e.g. school teachers, office
workers, sewing-factory workers. There was a higher
proportion of pensioners among the women than the
men (23 vs. 15%, respectively). Men had higher levels of
physical activity at work and consumed more alcohol,
with vodka binge drinking as a prevailing pattern. Men
also smoked substantially more. The prevalence rates of
visceral adiposity (as defined by both the NCEP and IDF
criteria), which is the core element in metabolic syn-
drome’s pathogenesis and the proxy-indicator of insulin-
resistance, was also much lower among men than
women in our study. A detailed analysis of the relation-
ships among MetS, its components, and life-style and
socio-demographic determinants among Russian adults
is beyond the scope of this paper.
Only one research publication was found that exam-
ined the prevalence of MetS among Russians [30]. It
was carried out in the Kuzmolovsky district (close to St.
Petersburg) and reported a much higher prevalence rate
(54% vs. 18.9% in our study). However, that study had
severe limitations: small sample size (146 participants),
questionable selection procedure (i.e. shifted gender and
age distribution; 91% were women with a mean age of
68 years), prevalence was reported without gender- and
age-standardization, and a high prevalence of co-mor-
bidity occurred (90% reported heart disease). Neverthe-
less, if we compare the results of that study with ours
for women in the age group 60+, the difference in MetS’
prevalence is reduced considerably (54% vs. 45%).
A population-based study of men living in Kuopio in
Eastern Finland [31] reported a prevalence of MetS
(using the NCEP definition) similar to ours (13.7% vs.
Table 3 Age-standardized
1 prevalence of the metabolic syndrome according to the AHA/NHLBI, NCEP and IDF
definitions
Prevalence, % (95% CI)
AHA/NHLBI NCEP IDF
World Russian World Russian World Russian
Men 13.7 (12.2-15.2) 15.3 (13.6-17.0) 11.5 (10.1-12.9) 12.9 (11.3-14.5) 11.0 (9.7-12.4) 12.3 (10.7-13.8)
Women 20.6 (18.9-22.3) 23.4 (21.5-25.4) 19.8 (18.1-21.5) 22.5 (20.6-24.5) 23.1 (21.3-24.9) 26.0 (24.0-28.0)
Total 17.0 (15.9-18.2) 19.3 (18.0-20.1) 15.5 (11.4-16.6) 17.6 (16.3-18.8) 16.8 (15.7-18.0) 18.9 (17.6-20.2)
1 Standardized to the Segi’s World standard population and the Russian population in 2002 by the following age-strata 20-29, 30-39, 40-49, 50-59, 60+ years.
Table 4 Kappa statistics () with standard errors (SE) for the agreement between the prevalence of metabolic
syndrome estimates obtained by three different diagnostic criteria
Agreement between the diagnostic criteria:  (SE)
Men (N = 1918) Women (N = 1637) Total(N = 3555)
NCEP and AHA/NHLBI 0.90 (0.02) 0.97 (0.01) 0.94 (0.01)M
NCEP and IDF 0.53 (0.03) 0.80 (0.02) 0.70 (0.02)
AHA/NHLBI and IDF 0.55 (0.03) 0.82 (0.02) 0.71 (0.02)
Sidorenkov et al. BMC Public Health 2010, 10:23
http://www.biomedcentral.com/1471-2458/10/23
Page 6 of 912.4% in our study). The population in that study was
older (mean age 52 years vs. 41.6 years in our study),
which might at least partly explain the higher prevalence
in the Finnish sample. However, the Finnish study was
performed in the late 1980s and more recent data from
Finland suggest that the current prevalence of the MetS
is higher. The results of a 2001 cross-sectional study in
Slovakia [32] were comparable to ours, with a similar
highly significant difference between men and women in
the prevalence of NCEP-defined MetS (15.9% vs. 23.9%).
However, there was no significant difference in IDF-
defined MetS between genders in the Slovakian study.
One may speculate about a specific distribution of the
MetS by gender in Eastern European countries, but
more data from this region are needed before definite
conclusions are drawn.
T h ep r e v a l e n c eo fM e t Si nt h eA r k h a n g e l s ks t u d y
increased progressively with age. This has also been
observed in other studies, but to a lesser extent [7-11].
In our study, there was a fifteen-fold increase among
women and a nine-fold increase among men when the
18-29 and 60+ age groups were compared. In the sub-
sample of individuals with MetS, the most frequent
metabolic abnormalities were arterial hypertension and
low HDL-C. Only one-third of men diagnosed with
MetS (NCEP) had central obesity, whereas more than
80% of women with MetS were obese. Interestingly,
although the prevalence of central obesity was higher
among women, the mean WC was higher among males
in all age groups.
T h em e t h o du s e dt od e f i n eo b e s i t y( B M I ,W Co r
WHR) strikingly affected the reported prevalence of this
condition in both genders. The variation was particularly
striking among men, ranging from 6% to 26% using the
WC and WHR definitions, respectively. By contrast,
among women, the frequency was highest when obesity
was defined by the WC-criteria. The original sex-specific
thresholds for WC were originally (at least partly) estab-
lished in cross-sectional studies from Holland and the
UK [33,34], using correlation between WC and BMI in
subjects with BMI ≥25 kg/m
2 and 30 kg/m
2.T h ec u t -
offs for obesity using WC depend on ethnicity [25].
According to the ROC analysis, the optimal cut-offs for
WCs corresponding to BMIs of ≥25 kg/m
2 and ≥30 kg/
m
2 w e r ea b o u t1 0c ml o w e r( ≥84 cm and ≥92 cm,
respectively) than the original one (≥94 cm and ≥102
cm, respectively) suggesting a lower tendency for central
a d i p o s i t ya tag i v e nB M Ia m o n gt h em e ni no u rs t u d y
setting. Similar results were reported from a study of
middle-aged eastern Finnish men in the late 1980
th [31].
On the contrary, the standard cut-offs of WC for
Table 5 Sex-specific prevalence of individual metabolic
abnormalities
1 among study participants with NCEP
diagnosed metabolic syndrome
Metabolic
abnormality
Prevalence
Men (N =
210)
Women (N =
347)
Total (N =
557)
% 95 % CI % 95 % CI % 95 % CI
Central obesity 37.1 30.6-
43.7
82.4 78.4-
86.5
65.4 61.4-
69.3
High TG 83.8 78.8-
88.8
71.2 66.4-
76.0
76.7 73.1-
80.2
Low HDL-C 85.7 80.9-
90.5
88.8 85.4-
92.1
87.6 84.9-
90.4
AH 93.8 90.5-
97.1
89.1 85.8-
92.4
90.8 88.4-
93.3
Elevated SG 33.3 26.9-
39.8
18.4 14.3-
22.5
24.1 20.5-
27.6
Elevated HBA1c 17.1 12.0-
22.3
14.4 10.7-
18.1
15.4 12.4-
18.5
1 Central obesity: WC ≥88 cm (women) and ≥102 cm (men); High TG:
triglycerides ≥1,7 mmol/l; Low HDL-C, high-density lipoprotein cholesterol
<1,29 mmol/l (women) and <1,04 mmol/l (men); Arterial hypertension (AH):
SBP ≥ 130 mmHg, or DBP ≥ 85 mmHg, or Rt for hypertension ; Elevated SG:
serum glucose ≥6.1 mmol/l or self-reported DM, or Rt for hyperglycemia;
Elevated HBA1c: glycated haemoglobin ≥6.1% or self-reported DM, or Rt for
hyperglycemia
Table 6 Age-standardized
1 prevalence of one or more metabolic abnormalities among those who were diagnosed with
metabolic syndrome according to NCEP definition
Number of abnormalities Prevalence
Men (N = 1918) Women (N = 1637) Total (N = 3555)
% 95 % CI % 95 % CI % 95 % CI
≥1 72.5 70.7-74.3 68.7 66.7-70.7 70.8 69.5-72.2
≥2 31.4 29.3-33.5 39.5 37.4-41.6 35.4 33.9-36.9
≥3 12.4 10.9-14.0 22.4 20.5-24.3 17.3 16.0-18.5
≥4 4.0 3.0-4.9 9.9 8.4-11.3 6.8 5.9-7.7
5 0.55 0.2-0.9 1.7 1.0-2.3 1.1 0.7-1.5
1 Standardized to the Russian population in 2002 by the following age-strata 20-29, 30-39, 40-49, 50-59, 60+ years.
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Page 7 of 9women (≥80 cm and ≥88 cm) originally corresponded
well to BMIs of 25 kg/m
2 and 30 kg/m
2.T h e r e f o r e ,t h e
original cut-offs used for WC in NCEP and IDF defini-
tions of MetS may be inappropriate for men living in
Northwest Russia. This is an important finding that
might largely explain the unequal distribution of MetS
by sex. The finding needs further verification.
The most reasonable explanation for our main find-
ings is the difference in life-style between Russian men
and women: women smoked less, had lower alcohol
consumption and, what is more important, lower levels
of physical activity. In general, Russian women have
occupations involving low levels of physical activity at
work (service sector, office personnel, workers in the
sewing industry), whereas men have higher levels of
work-related physical activity.
Our study did not support the hypothesis that the
high burden of cardiovascular morbidity and mortality
among Russian men could be attributed to a high preva-
lence of MetS. A high prevalence of smoking and life-
style associated with excessive alcohol consumption and
specific drinking patterns may be other contributors to
the high cardiovascular morbidity and mortality among
Russian men. Alcohol consumption was high in our
study population [35], especially among men. It might
have had a “protective” effect on the development of the
metabolic syndrome, but an opposite effect on the risk
of fatal cardiovascular events. An alcohol-related
increase in insulin sensitivity has been reported, invol-
ving a linearly-associated lower risk for MetS [36].
Nevertheless, alcohol consumption is an established risk
factor for CVD mortality in Russia [37]. Analyses of
associations between MetS and socio-demographic char-
acteristics, smoking, alcohol and other factors, as well as
cardiovascular risk attributable to MetS, are beyond the
scope of this paper and will be pursued in future
studies.
Differences in life expectancy between Russian men
and women (59.0 and 72.3 years in 2000, respectively)
may contribute to an explanation of the observed differ-
ences between genders in the prevalence of MetS [38],
suggesting that Russian men do not reach the age when
MetS becomes highly prevalent. Age-standardization,
however, leveled out this difference only partially, sug-
gesting that the difference in life expectancy is not the
only contributor to the gender difference in the preva-
lence of MetS in Russia.
Conclusion
While the prevalence of MetS among Russian women is
comparable to the data for Europe and the USA, the
prevalence among Russian men is considerably lower
than among their European and North-American coun-
terparts. Our results suggest that MetS is unlikely to be
a major contributor to high mortality from cardiovascu-
lar diseases among Russian men. Further studies of
determinants for MetS and its components, and MetS
and cardiovascular risk are needed for a better under-
standing of the mechanisms leading to the exceptionally
high cardiovascular mortality in Russia.
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